Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes

Cell Biology International

Volumn 34, Issue 11, 2010, Pages 1085-1089

  Bobak, Yaroslav P ^a   Vynnytska, Bozhena O ^a   Kurlishchuk, Yuliya V ^a   Sibirny, Andriy A ^a   Stasyk, Oleh V ^a  

^a INSTITUTE OF CELL BIOLOGY   (Ukraine)

Author keywords

Arginine deprivation; Cell death; Urea cycle enzyme

Indexed keywords

ARGINASE 1; ARGINASE 2; ARGININE; ARGININOSUCCINATE SYNTHASE; CITRULLINE; ORNITHINE; ORNITHINE CARBAMOYLTRANSFERASE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DNA FRAGMENTATION; ENZYME ACTIVITY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ARGINASE; ARGININE; ARGININOSUCCINATE SYNTHASE; CITRULLINE; EPITHELIAL CELLS; HUMANS; NEOPLASMS; ORNITHINE; ORNITHINE CARBAMOYLTRANSFERASE; TUMOR CELLS, CULTURED;

EID: 77957308674     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20100451     Document Type: Article

References (14)

1. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-8.
2. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001;61:1100-6.
3. Choi BS, Martinez-Falero IC, Corset C, Munder M, Modolell M, Muller I et al. Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages. J Leukocyte Biol 2009;85:268-77.
4. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
5. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010;126:2762-72.
6. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826-33.
7. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010;28:2220-6.
8. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887-99.
9. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-22.
10. Morris SM, Arginine: beyond protein. Am J Clin Nutr 2006;83:508S-12S.
11. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977;83:346-56.
12. Wheatley DN. Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin Cancer Biol 2005;15:247-53.
13. Wheatley DN, Kilfeather R, Stitt A, Campbell E. Integrity and stability of the citrulline-arginine pathway in normal and tumour cell lines. Cancer Lett 2005;227:141-52.
14. Yoon JH, Lee HS, Kim TH, Woo GH, Kim CY. Augmentation of ureasynthetic capacity by inhibition of nitric oxide synthesis in butyrateinduced differentiated human hepatocytes. FEBS Lett 2000;474:175-8.